Clodia Osipo, PhD | Loyola Medicine

COVID-19 (Coronavirus) Update

Loyola Medicine is resuming select health care services. Learn more about resumption of services.

Clodia Osipo, PhD

Cancer Biology

Associate Professor

Languages Spoken

English, Persian,Assyrian

Clinical Expertise

Biography

Interests
Family and Friends;Tennis;Swimming

Medical Education

Medical School
Residency
Fellowship

Board Certification

Research

  • Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer Fukushiro-Lopes, D. F.; Hegel, A. D.; Rao, V.; Wyatt, D.; Baker, A.; Breuer, E. K.; Osipo, C.; Zartman, J. J.; Burnette, M.; Kaja, S.; Kouzoukas, D. E.; Burris, S.; Jones, W. K.; Gentile, S.
  • Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1. Shah, D; Wyatt, D; Baker, AT; Simms, P; Peiffer, DS; Fernandez, M; Rakha, E; Green, A; Filipovic, A; Miele, L; Osipo, C, Clinical cancer research : an official journal of the American Association for Cancer Research
  • Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. Baker, A; Wyatt, D; Bocchetta, M; Li, J; Filipovic, A; Green, A; Peiffer, DS; Fuqua, S; Miele, L; Albain, KS; Osipo, C, Oncogene
View All ResearchShow Less
  • Deubiquitinase OTUD6B Isoforms Are Important Regulators of Growth and Proliferation Sobol, A.; Askonas, C.; Alani, S.; Weber, M. J.; Ananthanarayanan, V.; Osipo, C.; Bocchetta, M., Molecular cancer research : MCR
  • Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer Fukushiro-Lopes, D. F.; Hegel, A. D.; Rao, V.; Wyatt, D.; Baker, A.; Breuer, E. K.; Osipo, C.; Zartman, J. J.; Burnette, M.; Kaja, S.; Kouzoukas, D.; Burris, S.; Jones, W. K.; Gentile, S., Oncotarget
  • The role of Rak in the regulation of stability and function of BRCA1. Kim, JL; Ha, GH; Campo, L; Denning, MF; Patel, TB; Osipo, C; Lin, SY; Breuer, EK, Oncotarget
  • ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation Nunes, J.; Zhang, H.; Angelopoulos, N.; Chhetri, J.; Osipo, C.; Grothey, A.; Stebbing, J.; Giamas, G., Oncotarget
  • Cancer stem cells and HER2 positive breast cancer: The story so far. Shah, D; Osipo, C, Genes & diseases
  • Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival Das, S.; Sondarva, G.; Viswakarma, N.; Nair, R. S.; Osipo, C.; Tzivion, G.; Rana, B.; Rana, A., The Journal of biological chemistry
  • PKCalpha Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance Pandya, K.; Wyatt, D.; Gallagher, B.; Shah, D.; Baker, A.; Bloodworth, J.; Zlobin, A.; Pannuti, A.; Green, A.; Ellis, I. O.; Filipovic, A.; Sagert, J.; Rana, A.; Albain, K. S.; Miele, L.; Denning, M. F.; Osipo, C., Clinical cancer research : an official journal of the American Association for Cancer Research
  • The role of Rak in the regulation of stability and function of BRCA1 Kim, J. L.; Ha, G. H.; Campo, L.; Denning, M. F.; Patel, T. B.; Osipo, C.; Lin, S. Y.; Breuer, E. K., Oncotarget
  • Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer Baker, A. T.; Zlobin, A.; Osipo, C., Frontiers in oncology
  • Osteopontin mediates an MZF1-TGF-beta1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer Weber, C. E.; Kothari, A. N.; Wai, P. Y.; Li, N. Y.; Driver, J.; Zapf, M. A.; Franzen, C. A.; Gupta, G. N.; Osipo, C.; Zlobin, A.; Syn, W. K.; Zhang, J.; Kuo, P. C.; Mi, Z., Oncogene
  • Crosstalk between PKCalpha and Notch-4 in endocrine-resistant breast cancer cells Yun, J.; Pannuti, A.; Espinoza, I.; Zhu, H.; Hicks, C.; Zhu, X.; Caskey, M.; Rizzo, P.; D'Souza, G.; Backus, K.; Denning, M. F.; Coon, J.; Sun, M.; Bresnick, E. H.; Osipo, C.; Wu, J.; Strack, P. R.; Tonetti, D. A.; Miele, L., Oncogenesis
  • Evaluation of biomarkers in multifocal/multicentric invasive breast carcinomas Pekmezci, M.; Szpaderska, A.; Osipo, C.; Ersahin, C., International Journal of Surgical Pathology
  • Gamma secretase inhibitors of Notch signaling Olsauskas-Kuprys, R.; Zlobin, A.; Osipo, C., OncoTargets and therapy
  • The functional role of notch signaling in triple-negative breast cancer Speiser, J. J.; Ersahin, C.; Osipo, C., Vitamins and hormones
  • The Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma, Pekmezci, M.; Szpaderska, A.; Osipo, C.; Ersahin, C., Pathology research international
  • NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications Clementz, A. G.; Rogowski, A.; Pandya, K.; Miele, L.; Osipo, C., Breast cancer research : BCR
  • Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Pandya, K.; Meeke, K.; Clementz, A. G.; Rogowski, A.; Roberts, J.; Miele, L.; Albain, K. S.; Osipo, C., British journal of cancer
  • Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Hao, L.; Rizzo, P.; Osipo, C.; Pannuti, A.; Wyatt, D.; Cheung, L. W.; Sonenshein, G.; Osborne, B. A.; Miele, L., Oncogene
  • Targeting Notch signaling cross-talk with estrogen receptor and ErbB-2 in breast cancer Rizzo, P.; Osipo, C.; Pannuti, A.; Golde, T.; Osborne, B.; Miele, L., Advances in Enzyme Regulation
  • Trastuzumab resistance: role for Notch signaling Mehta, K.; Osipo, C., Thescientificworldjournal
  • Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches Rizzo, P.; Miao, H.; D'Souza, G.; Osipo, C.; Song, L. L.; Yun, J.; Zhao, H.; Mascarenhas, J.; Wyatt, D.; Antico, G.; Hao, L.; Yao, K.; Rajan, P.; Hicks, C.; Siziopikou, K.; Selvaggi, S.; Bashir, A.; Bhandari, D.; Marchese, A.; Lendahl, U.; Qin, J. Z.; Tonetti, D. A.; Albain, K.; Nickoloff, B. J.; Miele, L., Cancer research
  • ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Osipo, C.; Patel, P.; Rizzo, P.; Clementz, A. G.; Hao, L.; Golde, T. E.; Miele, L., Oncogene
  • Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Osipo, C.; Golde, T. E.; Osborne, B. A.; Miele, L. A., Laboratory Investigation
  • Rational targeting of Notch signaling in cancer Rizzo, P.; Osipo, C.; Foreman, K. E.; Golde, T.; Osborne, B.; Miele, L., Oncogene
  • Intracellular distribution of TiO2-DNA oligonucleotide nanoconjugates directed to nucleolus and mitochondria indicates sequence specificity Paunesku, T.; Vogt, S.; Lai, B.; Maser, J.; Stojicevic, N.; Thurn, K. T.; Osipo, C.; Liu, H.; Legnini, D.; Wang, Z.; Lee, C.; Woloschak, G. E., Nano letters
  • Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. Osipo, C.; Meeke, K.; Cheng, D.; Weichel, A.; Bertucci, A.; Liu, H.; Jordan, V. C., International journal of oncology
  • Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells Liu, H.; Cheng, D.; Weichel, A. K.; Osipo, C.; Wing, L. K.; Chen, B.; Louis, T. E.; Jordan, V. C., International journal of oncology
  • Hedgehog signaling in hepatocellular carcinoma: novel therapeutic strategy targeting hedgehog signaling in HCC Osipo, C.; Miele, L., Cancer Biology & Therapy
  • Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal Lewis, J. S.; Osipo, C.; Meeke, K.; Jordan, V. C., The Journal of steroid biochemistry and molecular biology
  • MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis Levenson, A. S.; Thurn, K. E.; Simons, L. A.; Veliceasa, D.; Jarrett, J.; Osipo, C.; Jordan, V. C.; Volpert, O. V.; Satcher, R. L., Jr; Gartenhaus, R. B., Cancer research
  • Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy Osipo, C.; Gajdos, C.; Cheng, D.; Jordan, V. C., The Journal of steroid biochemistry and molecular biology
  • Trastuzumab therapy for tamoxifen-stimulated endometrial cancer Osipo, C.; Meeke, K.; Liu, H.; Cheng, D.; Lim, S.; Weichel, A.; Jordan, V. C., Cancer research
  • The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death Osipo, C.; Liu, H.; Meeke, K.; Jordan, V. C., Experimental biology and medicine (Maywood, N.J.)
  • Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo Liu, H.; Lee, E. S.; Gajdos, C.; Pearce, S. T.; Chen, B.; Osipo, C.; Loweth, J.; McKian, K.; De Los Reyes, A.; Wing, L.; Jordan, V. C., Journal of the National Cancer Institute
  • Changing role of the oestrogen receptor in the life and death of breast cancer cells Jordan, V. C.; Osipo, C.; Schafer, J. M.; Fox, J. E.; Cheng, D.; Liu, H., Breast (Edinburgh, Scotland)
  • Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer Osipo, C.; Gajdos, C.; Liu, H.; Chen, B.; Jordan, V. C., Journal of the National Cancer Institute
  • Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors Osipo, C.; Dorman, S.; Frankfater, A., Experimental cell research